Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Jessica Smith

Nurse Practitioner, Women's Health East Ridge, TN Nurse Practitioner

NPI 1821712985 CMS profile 11414402

961 Spring Creek Rd Ste 202, East Ridge, TN 37412

Open in the dashboard

General payments

$4,636

168 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jessica Smith of East Ridge, TN is reported in the CMS Open Payments database as having received $4,636 across 168 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Women's Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $487 25
2024 General $519 29
2023 General $3,107 103
2022 General $522 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessica Smith
  • Nurse Practitioner, Women's Health median
  • Middle half of Nurse Practitioner, Women's Health
  • National median

In program year 2025, general payments to Jessica Smith were reported at $487. Among 3,829 Nurse Practitioner, Women's Health profiles paid that year, the median was $124 and the middle half received between $42 and $307.

Show as a table
Year Jessica Smith Nurse Practitioner, Women's Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $110 $33–$291 $132
2022 $522 $122 $40–$314 $149
2023 $3,107 $131 $40–$333 $160
2024 $519 $123 $43–$298 $164
2025 $487 $124 $42–$307 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Axonics Modulation Technologies, Inc. $1,725 17 payments
  2. Medtronic, Inc. $905 22 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $552 50 payments
  4. Sumitomo Pharma America, Inc. $519 32 payments
  5. Astellas Pharma US Inc $373 19 payments
  6. Millicent US Inc $112 6 payments
  7. Lilly USA, LLC $96 3 payments
  8. Myovant Sciences Inc. $76 4 payments
  9. Mayne Pharma Inc. $54 4 payments
  10. AbbVie, Inc. $45 2 payments
  11. Other $179 9 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $3,073 160 payments
  2. Travel and Lodging $1,562 8 payments
Products named General payments · program years 2022–2025
  1. Axonics $1,725 17 payments
  2. INTERSTIM $895 21 payments
  3. RELISTOR Gastroenterology $536 48 payments
  4. MYFEMBREE Hormone Therapy $398 26 payments
  5. Veozah $338 17 payments
  6. RELISTOR Gastroenterology $317 28 payments
  7. Bulkamid $123 3 payments
  8. GEMTESA $114 6 payments
  9. MOUNJARO $96 3 payments
  10. MYFEMBREE Womens Health $82 4 payments
  11. Other $540 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

648

Median for Nurse Practitioner: 389

Drug cost

$114,092

Median for Nurse Practitioner: $21,885

Branded share of claims

52.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 21 $41,893
Gemtesa Vibegron Brand 29 $27,363
Mounjaro Tirzepatide Brand 12 $12,581
Myrbetriq Mirabegron Brand 11 $12,390
Estradiol Generic 73 $5,588
Estradiol (Twice Weekly) Estradiol Brand 29 $3,444
Progesterone Progesterone, Micronized Brand 47 $2,907
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 98 $2,400
Gabapentin Generic 94 $1,484
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 48 $998

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$3,082

Medicare's payments for the services billed

Medicare patients

31

Average age 72

Services billed

42

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 65%
Diabetes 52%
Ischemic heart disease 45%
Chronic kidney disease 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $141
$141 — —
Veozah
  • Astellas Pharma US Inc $58
$58 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $36
$36 — —
INTRAROSA
  • MILLICENT US INC $22
$22 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $16
$16 29 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

168 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Women's Health in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record